New resource available view now

News

100_IGC-Pharma-Reports-First-Quarter-2026-Financial-Results-with-CALMA-Phase-2-in-the-final-stage,-with-80Enrollment (1)

IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment

99_IGC-Pharma-Reaches-85-Enrollment-in-Phase-2-CALMA-Trial-Evaluating-IGC-AD1-for-Alzheimer’s-Agitation (1)

IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference

Poster_IA

Decoding Tau Heterogeneity: IGC Pharma Presents Novel Biomarker Research at the 2026 Global Tau Conference

98_IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase (1)

IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase

97_IGC-Pharma-Adds-Kerwin-Medical-Center-in-Dallas-to-Phase-2-CALMA-Trial-as-Enrollment-Advances-Toward-Completion (1)

IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion

96_IGC-Pharma-Secures-Psilocybin-Research-Authorization,-Expanding-Focus-on-Neuropsychiatric-Symptoms-in-Dementia- (1)

IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia

95_IGC-Pharma-Reports-Approximately-80-Patient-Enrollment-in-Phase-2-CALMA-Alzheimers-Agitation-Trial- (1)

IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout

94_IGC-Pharma-Announces-Coverage-Report-by-Ascendiant-Capital-Markets-about-the-“Reports-Q3. (1)

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts

93_IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer’s Disease

IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer’s Disease.

91_IGC-Pharma-Reports-Financial-Results-and-Clinical-Progress-for-the-Transition-Period-Ended-December-31,-2025 (1)

IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025